Drug use evaluation is DUE: Healthcare utilization evaluation is over-DUE

Hospital Pharmacy

Volumn 31, Issue 4, 1996, Pages 347-353

  Bowman, Lee ^a,b  

^a ST VINCENT HOSPITAL   (United States)

^b NONE   (United States)

Author keywords

clinical outcome; drug use evaluation; drug utilization review; healthcare utilization

Indexed keywords

HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITAL PHARMACY; REVIEW; TREATMENT OUTCOME; UTILIZATION REVIEW;

EID: 0029923158     PISSN: 00185787     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (98)

1. Blackburn JL. Impact of drug usage review on drug utilization. Pharmacoeconomics 1993; 3:14-2.
2. Brodie DC, Smith WE. Constructing a conceptual model of drug utilization review Hospitals 1976, 50:143-50.
3. Stolar M. Drug use review: Operational definitions. Am J Hosp Pharm 1978; 33: 225-30
4. Joint Commission on Accreditation of Healthcare Organizations. Accreditation manual for hospitals 1990. Chicago: Joint Commission on Accreditation of Healthcare Organizations, 1989.
5. Social Security Act. section 1927, title XIX. Omnibus Budget and Reconciliation Act of 1990.
6. Erwin WG. The definition of drug utilization review: Statement of issues. Clin Pharmacol Ther 1991; 50,596-99.
7. Armstrong EP, Terry AK. Impact of drug use evaluation upon ambulatory pharmacy practice. Ann Pharmacother 1992; 26 1546-53.
8. Rucker TD. The need for drug utilization review Am J Hosp Pharm 1970; 27 654-58.
9. Gregory JM, Knapp DE. State-of-the-art of drug usage review. Am J Hosp Pharm 1976; 33:925-28.
10. Bergman HD. Prescribing of drugs in a nursing home. Drug Intell Clin Pharm 1975; 9:356-69.
11. Deliganis SG, Johnson SR. Computerless drug use review. Hospitals 1973; 47: 86-93.
12. Ellinoy BJ, Mays JF, McSherry PU, Rosenthal LC. Pharmacy audit of patient health records-feasibility and usefulness of a drug surveillance system. Am J Hosp Pharm 1972; 29-749-54.
13. Hood JC, Lemberger MA, Stewart RB. Promoting appropriate therapy in a longterm care facility. J Am Pharm Assoc 1975; NS15:32-37.
14. Kelly WN, White JA. Miller DE Drug usage review in a community hospital. Am J Hosp Pharm 1975, 32:1014-17.
15. Knapp DA, et al. Incorporating diagnosis into drug use review system, final report. School of Pharmacy, University of Maryland at Baltimore, December 1975.
16. Letoumeau KN. Drug utilization review in an extended care facility. Drug Intell Clin Pharm 1974; 8:108-14.
17. Maronde ER. Drug utilization review with on-line computer capability. Social Security Administration, Washington, DC 1973.
18. Miles DL, Ficken RP. Drug prescribing patterns in a rural setting, Drugs Health Care 1975; 2,187-94.
19. Miller RR. Measuring the influence of continuing education of drug prescribing-an exploratory study. Drug Inf J 1973; 737-47.
20. Pierpaoli PG, Bowman GK Drug utilization review/implementation. Hospitals 1972; 46:95-104.
21. Roden DR, Kennard LH. The utility of an organized drug database in determining contributions to the quality and efficiency of Medicaid programs. Drug Inf J 1975; 9:131-37
22. Stewart JE, Kabat HF, Wertheimer AI. Drug usage review sample studies in longterm care facilities. Am J Hosp Pharm 1976; 33:138-44.
23. Gibbs CW, Bigson JT, Newton DS. Drug utilization review of actual versus preferred pediatric antibiotic therapy. Am J Hosp Pharm 1973; 30:892-97.
24. Gibson JT, Hanley EE. Newton DS. Intravenous antibiotic usage in high risk patients compared to FDA-approved usage. Am J Hosp Pharm 1973, 30:116-23.
25. Jacinto MS, Kleinman K, Margolin J. Pharmacist-monitored, computerized drug usage review. Am J Hosp Pharm 1974; 31:508-12.
26. Petrello MA, Linkewich JA, Gluckman SJ, Flack HC. Clindamycin prescribing patterns in a university hospital. Am J Hosp Pharm 1975; 32:1111-15.
27. Resztak KE, Williams RB. A review of antibiotic therapy in patients with systemic infections. Am J Hosp Pharm 1972; 29:935-41
28. Roberts AW, Visconti JA. The rational and irrational use of systemic antimicrobial drugs. Am J Hosp Pharm 1972; 29:828-34.
29. Zeman BT, Pike M, Samet C. The antibiotic utilization committee. Hospitals 1974; 48:73-6.
30. O'Connell HM, Chance S, Bowman L. Computerized drug-use evaluation. Am J Hosp Pharm 1994; 51:363-67.
31. McDonald CJ. Protocol based computer reminders, the quality of care and the non-perfectibility of man. N Engl J Med 1976; 295:1351-55.
32. Hoffman RP. Using the PAS system for hospital drug utilization review. Hosp Prog 1979; 60:54-68.
33. Hlynka JN, Smith Jr. WE, Brodie DC. Developing drug-use profiles from drugcharge records. Am J Hosp Pharm 1979; 36:1347-51.
34. Mehl B. Use of electronic data processing for drug utilization review. Q Rev Bull 1979; 5:13-16.
35. Strom BL, Carson JL. Medicaid billing data used to study the effects of marketed drugs. Drug Info J 1987; 44:477-83.
36. Stergachis AS. Record linkage studies for postmarketing drug surveillance: Data quality and validity considerations. Drug Intell Clin Pharm 1988; 22:157-61.
37. Ognibene PJ. Smart pharmacy cards to automate patient records for prospective drug utilization review. Proc Annu Symp Comput Appl Med Care 1991: 906-08.
38. Tierney WM. Miller ME, Overhage JM, McDonald CJ. Physician inpatient order writing on microcomputer workstations: Effects on resource utilization. JAMA 1993; 269:379-83.
39. Levine GM, Deardeuff JC. NCPDPs concurrent drug utilization review standard: A blueprint for improving the management of pharmaceutical care. Drug Benefit Trends 1992; 4:3-8.
40. Fish CA, Kirking DM, Martin JB Information systems for evaluating the quality of prescribing Ann Pharmacother 1992; 26, 392-8.
41. Grasela TH. Walawander CA, Kennedy DL, Jolson HM. Capability of hospital computer systems in performing drug-use eval-uations and adverse drug event monitoring. Am J Hosp Pharm 1993; 50:1889-95.
42. Reed DM, Hepler CD, Helling DK. An tibiotic use review in ambulatory care using computer-assisted medical record audit Am J Hosp Pharm 1982; 39:280-84.
43. Helling DK, Hepler CD, Herman RA. Comparison of computer-assisted medical record audit with other drug use review methods Am J Hosp Pharm 1979; 36,1665-71.
44. Principi N, Sher D. Moresco RC, et al. Control of antibiotic therapy in pediatric patients. Dev Pharmacol Ther 1981; 2:145-55.
45. Huckleberry SD. Antibiotic cost-containment. Drug Intell Clin Pharm 1986; 20: 589-91.
46. Helling DK, Norwood GJ, Donner JD. An assessment of prescribing using drug utilization review criteria. Drug Intell Clin Pharm 1982; 16:930-34.
47. Brodie DC. Lofholm P, Benson RA. A model for drug use review in a skilled nursing facility. J Am Pharm Assoc 1977; 10: 617-20.
48. Hekster YA, Friesen WT, Boerema JBJ. Record linked audit of drug utilization data in a hospital: Antimicrobial use on a urology ward. J Clin Hosp Pharm 1981; 6:277-83
49. Garibaldi RA, Burke J. Surveillance and control of antibiotic use in the hospital. Am J Infect Control 1991; 19:164-70.
50. Kunin CM, Efrom HY. Guidelines for peer review: Veterans administration ad hoc interdisciplinary advisory committee on antimicrobial drug usage. JAMA 1977; 237:1001-2.
51. Brandon BM, Knapp DA, Klein LS, Gregory J. Drug usage screening criteria. Am J Hosp Pharm 1977; 34:146-51.
52. Barriere SL, Conte Jr. JE. Aminoglycoside use monitored by clinical pharmaceutical services. Am J Hosp Pharm 1979; 36, 1209-11.
53. Smith KS, Quercia RA. Chow MSS, et al. Multidisciplinary program for promoting single prophylactic doses of cefazolin in obstetrical and gynecological surgical procedures. Am J Hosp Pharm 1988, 45:1338-42.
54. Pastel DA, Chang S, Nessim S. Shane R. Morgan MA. Department of pharmacyinitiated program for streamlining empirical antibiotic therapy. Hosp Pharm 1992; 27: 596-603.
55. Pelletier LL. Hospital usage of parenteral antimicrobial agents: A graduated utilization review and cost-containment program. Infect Control 1985; 6:226-30.
56. Green ER, Chrymko MM. Rozek SL, Kitrenos JG. Clinical considerations and costs associated with formulary conversion of tobramycin to gentamicin. Am J Hosp Pharm 1989, 46,714-19.
57. Franson TR, DaMert GJ, Sheth NK, et al Institution-specific versus published in vitro antimicrobial susceptibility data in making formulary decisions. Am J Hosp Pharm 1987; 44:95-101.
58. Classen DC, Evans RS, Pestotnik SL, et al. The timing of prophylactic administration of antibiotics and the risk of surgicalwound infection. N Engl J Med 1992; 326: 281-86
59. Evans RS, Burke JP, Classen DC, et al. Computerized identification of patients at high risk for hospital acquired infection. Am J Infect Control 1992; 20:4-10.
60. Evans RS, Pestotonik SL, Classen DC, Burke JP. Development of an automated antibiotic consultant. MD Comput 1993; 10: 17-22.
61. Larsen RA, Evans RS, Burke JP, et al. Improved perioperative antibiotic use and reduced surgical wound infections through use of a computer decision analysis. Inf Control Hosp Epid 1989; 10:316-20.
62. Evans RS, Pestotnik SL, Burke JP, et al. Reducing the duration of prophylactic antibiotic use through computer monitoring of surgical patients. DICP 1990; 24:351-54.
63. Schwartz JI, Kennedy TJ. Computerassisted practitioner-response system for studying the use of cimetidine. Am J Hosp Pharm 1982; 39:1198-1201.
64. Lipowski EE, Bauwens SF, Collins TM. An examination of histamine-2 receptor antagonist use by Medicaid recipients in Wisconsin long-term care facilities. J Am Ger Soc 1988; 35:531-35.
65. Douglas KC, Dykstra AM. Fitzpatrick W, et al. H2 receptor antagonist usage in Missouri Medicaid recipients. Mo Medicine 1988; 85:779-80.
66. Segal R, Russel WL, Taeho O, BenJoseph R. Use of IV cimetidine, raniditine and famotidine in 40 hospitals. Am J Hosp Pharm 1993; 50:2077-81.
67. Kono KM, Johnson WF, Anderson PO, Sato LA, Simonian RI. Effects of a pharmacybased cost-containment program on cimetidine costs and use. Am J Hosp Pharm 1987; 44: 2068-73
68. Klapp D, Harrison WL. Evaluation of albumin use by medical audit. Am J Hosp Pharm 1979; 36:1205-09.
69. Gales BJ, Erstad BL. Albumin audit results and guidelines for use. Pharm Technol 1992; 8:125-29.
70. Stratton TP, Plachetka JR, Gaines JA. Cost savings from hetastarch use in place of albumin on a cardiothoracic surgery service. Hosp Form 1984; 19:571-72
71. Forrester L, Ballentine R, Dane WJ. Human serum albumin usage in a comprehensive cancer center. Contemp Pharm Pract 1980; 3:134-40
72. Donnelly AJ. Albumin/hetastarch drug utilization review in an operating room pharmacy. DICP 1987; 21:286-89.
73. Chien CP, Solomon K. Platek TE. Macro-monitoring. A step toward rational psychopharmacotherapy. Am J Hosp Pharm 1978; 35:397-402.
74. Bergman U, Christenson I. Jansson B. Wiholm BE. Auditing hospital drug utilization by means of define daily doses per bed-day: A methodological study. Eur J Clin Pharmacol 1980; 17:183-87.
75. Sherman D. Using common sense to reduce antipsychotic drug use. Contemp Longterm Care 1991; 14:68-70.
76. Braulen J, Rafalowicz E, Yellowlees P. Psychotropic drug prescribing in a general hospital inpatient psychiatric unit. Aust N Z J Psychiatry 1989; 23:352-55.
77. Boisseree VR, Keith JC, Little DC. The Valium project: Diagnostic restrictions as a utilization control in a Medicaid drug program. Health Care Financing Review 1984; 5:133-38.
78. Skaer TL, Sclar DA. Robison LM, Won JKH, Markowski DJ Effect of pharmaceutical formulation on health care expenditures for hypertension: A study of verapamil in a Medicaid population. Curr Ther Research 1993, 53:256-64.
79. Einarson TR, Segal HJ. Mann JL Drug utilization in Canada. J Soc Admin Pharm 1989; 6:69-82.
80. Petros WP, Shank WA. A standardized parenteral nutrition solution: Prescribing, use, processing and material cost implications. Hosp Pharm 1986; 21,654-56.
81. Colligen BH, Levy RA. Commentary: The formulary process in managed care, hidden costs and doubtful benefits. Pharm Ther 1992; 10:1290-1293.
82. Hammel RW. Insights into public assistance medical care expenditures. JAMA 1972; 219:1740-44.
83. Smith DM, McKercher PL. The elimination of selected drug products from the Michigan Medicaid formulary. A case study. Hosp Form 1984; 19:366-72.
84. Moore WJ, Newman RJ, An economic analysis of state Medicaid formularies: Implications for the recent changes in the Louisiana formulary. Doctoral Dissertation, Department of Economics, Louisiana State university (1989).
85. Reeder EC, Lingle EW. An evaluation of the South Carolina Medicaid open formulary system. Final report submitted to the national Pharmaceutical Council, Inc December 29, 1988.
86. Kozma CM, Reeder CE, Lingle EW. Expanding Medicaid drug formulary coverage: Effect on utilization of related services. Med Care 1990, 28.963-77.
87. Dranove D. Medicaid drug formulary restrictions. J Law Econ 1989; 37:143-62.
88. Anon Medicines in Medicaid: Cost effective health care for America's poor. Pharmaceutical Manufacturers Association. April 1990
89. Frankl SE, Breeling JL, Goldman L. Preventability of emergent hospital readmission Am J Med 1991; 90:667-74.
90. Sloan FA, Gordon GS, Cocks DL Hospital drug formularies and use of hospital services. Med Care 1993; 31:851-67.
91. Knapp DA. Erwin WG. Model for developing strategies for outpatient drug use review. HCFA Project cooperative agreement No 17-C-99406/3-01.
92. Soumerai SB, McLaughlin TJ, Avorn J. Improving drug prescribing in primary care. A critical analysis of the experimental literature. Milbank Q 1989; 67:268-317.
93. Mitchell JL. CQI: Changing systems to improve quality. Am Phar 1992; NS32:47-53.
94. Jones DJ, Ziegenfuss JT The administrative and clinical rationale for the total organization approach to continuous quality improvement. Am J Med Qual 1993; 8:112-6.
95. Kibbe DC, Bentz L, McLaughlin CP. Continuous quality improvement for continuity of care J Fam Pract 1993; 36:304-8.
96. Cesta TG. The link between Continuous quality improvement and case management. J Nurs Admin 1993; 23:66-69.
97. Waggoner DM Application of continuous quality improvement techniques to the treatment of patients with hypertension. Health Care Manage Rev 1992; 17:33-42.
98. Zablocki E Using information systems to improve care and manage costs. The Quality Letter 1995; 7:2-10.